Studies have indicated that PLD is less extruded by pegylation and inhibits pump activity compared to Adriamycin, suggesting that PLD may be more effective against drug-resistant lymphomas than conventional Adriamycin (25). The gene discussed is GPLD1; the disease is lymphoma.